Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Halozyme Therapeutics (HALO) Acquisitions (2026)

Halozyme Therapeutics has reported Acquisitions over the past 1 years, most recently at $710000.0 for Q1 2026.

Quarterly Acquisitions changed N/A to $710000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $710000.0 through Mar 2026, changed N/A year-over-year, with the annual reading at $726.0 million for FY2025, N/A changed from the prior year.
Acquisitions was $710000.0 for Q1 2026 at Halozyme Therapeutics.
Over five years, Acquisitions peaked at $710000.0 in Q1 2026 and troughed at $710000.0 in Q1 2026.